7,376.86

+23.13

+0.31%

51,285.73

-237.33

-0.46%

24,579.42

+264.43

+1.09%

2,754.11

+24.22

+0.89%

4.8590

+0.0220

+0.45%

25.64

-2.54

-9.01%

4,074.90

-38.60

-0.94%

75,890.26

+249.60

+0.33%

Crude Oil Dec 26

90.83

+0.31

+0.34%

US Private Equity

10,772.76

+11.83

+0.11%

KOSDAQ - Delayed Quote KRW

HLB Co., Ltd. (028300.KQ)

31,250.00 -1,150.00 (-3.55%)

At close: November 6 at 3:30:14 PM GMT+9

Loading Chart for 028300.KQ

Chart Range Bar

Interval:

In partnership with ChartIQ

Elevar Therapeutics Announces FDA PDUFA Date for Resubmitted New Drug Application for Rivoceranib in Combination With Camrelizumab for Use as a First-line Systemic Treatment for Unresectable or Metastatic Hepatocellular Carcinoma

Elevar Therapeutics Announces FDA PDUFA Date for Resubmitted New Drug Application for Rivoceranib in Combination With Camrelizumab for Use as a First-line Systemic Treatment for Unresectable or Metastatic Hepatocellular Carcinoma

Elevar Therapeutics Receives FDA Conditional Acceptance of LYRFIGTU as Brand Name for Lirafugratinib

Elevar Therapeutics Submits Marketing Authorization Application to European Medicines Agency for Lirafugratinib as a Treatment for Patients with Advanced/Metastatic Cholangiocarcinoma (CCA) Harboring FGFR2 Fusions or Rearrangements

Elevar Therapeutics Submits Marketing Authorization Application to European Medicines Agency for Lirafugratinib as a Treatment for Patients with Advanced/Metastatic Cholangiocarcinoma (CCA) Harboring FGFR2 Fusions or Rearrangements

Elevar Therapeutics to Share Camrelizumab/Rivoceranib Poster at International Liver Cancer Association Conference on Clinical Outcomes in Younger Age Patients with Unresectable Hepatocellular Carcinoma

Elevar Therapeutics to Share Camrelizumab/Rivoceranib Poster at International Liver Cancer Association Conference on Clinical Outcomes in Younger Age Patients with Unresectable Hepatocellular Carcinoma

Elevar Therapeutics Resubmits New Drug Application to FDA for Combination of Camrelizumab plus Rivoceranib for Use as a First-line Treatment Option for Unresectable or Metastatic Hepatocellular Carcinoma

Elevar Therapeutics Resubmits New Drug Application to FDA for Combination of Camrelizumab plus Rivoceranib for Use as a First-line Treatment Option for Unresectable or Metastatic Hepatocellular Carcinoma

Mobilize your Website

View Site in Mobile | Classic

Share by: